



RWANDA – PNEUMOCOCCAL VACCINE SUPPORT
This Decision Letter sets out the Programme Terms of a Programme

1. Country: Rwanda				
2. Grant Number: 0915-RWA-12c-X				
3. Date of Decision Letter : 21 October 2013				
4. Date of the Partnership Framework Agreement: 07 June 2013				
5. Programme Title: New Vaccine Support				
6. Vaccine type: Pneumococcal				
7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV13), 1 dose(s) per vial , LIQUID				
8. Programme Duration¹: 2009-2015				
9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):				
	2009-2013	2014	2015	Total ²
Programme Budget (US\$)	US\$18,741,533 ³	US\$3,999,500	US\$5,725,000	US\$28,466,033
10. Vaccine Introduction Grant: N/A				
11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement)⁴:				
Type of supplies to be purchased with GAVI funds in each year	2009-2013	2014		
Number of Pneumococcal vaccines doses		759,500		
Number of AD syringes		829,000		
Number of safety boxes		9,225		
Annual Amounts (US\$)	US\$18,741,533 ⁵	US\$3,999,500		
12. Procurement agency: UNICEF. The Country shall release its Co-Financing Payments each year to UNICEF.				
13. Self-procurement: N/A				

¹ This is the entire duration of the programme.

² This is the total amount endorsed by GAVI for the entire duration of the programme. This should be equal to the total of all sums in the table.

³ This is the consolidated amount for all previous years.

⁴ This is the amount that GAVI has approved. Please amend the indicative Annual Amounts from previous years if that changes subsequently.

⁵ This is the consolidated amount for all previously approved years.

14. Co-financing obligations: Reference code: 0915-RWA-12c-X-C - According to the Co-Financing Policy, the Country falls within the group Low Income. The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2014	2015
Number of vaccine doses	44,800	61,900
Value of vaccine doses (US\$)	US\$151,742	
Total Co-Financing Payments (US\$) (including freight)	US\$161,000	US\$220,000

15. Operational support for campaigns: N/A

	2014	2015
Grant amount (US\$)		

16. Additional documents to be delivered for future disbursements:

Reports, documents and other deliverables	Due dates
Annual Progress Report	15 May 2014

17. Financial Clarifications: The Country shall provide the clarifications stated in the IRC report attached as appendix C to GAVI*.

**Failure to provide the financial clarifications requested may result in GAVI withholding further disbursements*

18. Other conditions: N/A

Signed by,



On behalf of the GAVI Alliance

Hind Khatib-Othman

Managing Director, Country Programmes

21 October 2013

RWANDA – PENTAVALENT VACCINE SUPPORT
This Decision Letter sets out the Programme Terms of a Programme

1. Country: Rwanda				
2. Grant Number: 0715-RWA-04a-X				
3. Date of Decision Letter : 21 October 2013				
4. Date of the Partnership Framework Agreement: 07 June 2013				
5. Programme Title: New Vaccine Support				
6. Vaccine type: Pentavalent				
7. Requested product presentation and formulation of vaccine: DTP-HepB-Hib, 1 dose(s) per vial, LIQUID				
8. Programme Duration ⁶ : 2002-2015				
9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):				
	2002-2013	2014	2015	Total ⁷
Programme Budget (US\$)	US\$40,642,755 ⁸	US\$1,622,500	US\$2,092,000	US\$44,357,255
10. Vaccine Introduction Grant: N/A				
11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement) ⁹ :				
Type of supplies to be purchased with GAVI funds in each year	2002-2013	2014		
Number of Pentavalent vaccines doses		766,800		
Number of AD syringes		879,000		
Number of safety boxes		9,775		
Annual Amounts (US\$)	US\$40,642,755 ¹⁰	US\$1,622,500		
12. Procurement agency: UNICEF. The Country shall release its Co-Financing Payments each year to UNICEF.				
13. Self-procurement: N/A				

⁶ This is the entire duration of the programme.

⁷ This is the total amount endorsed by GAVI for the entire duration of the programme. This should be equal to the total of all sums in the table.

⁸ This is the consolidated amount for all previous years.

⁹ This is the amount that GAVI has approved. Please amend the indicative Annual Amounts from previous years if that changes subsequently.

¹⁰ This is the consolidated amount for all previously approved years.

14. Co-financing obligations: Reference code: 0715-RWA-04a-X-C - According to the Co-Financing Policy, the Country falls within the group Low Income. The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2014	2015
Number of vaccine doses	83,000	107,600
Value of vaccine doses (US\$)	US\$161,649	
Total Co-Financing Payments (US\$) (including freight)	US\$170,000	US\$220,000

15. Operational support for campaigns: N/A

	2014	2015
Grant amount (US\$)		

16. Additional documents to be delivered for future disbursements:


Reports, documents and other deliverables	Due dates
Annual Progress Report	15 May 2014

17. Financial Clarifications: The Country shall provide the clarifications stated in the IRC report attached as appendix C to GAVI*.

**Failure to provide the financial clarifications requested may result in GAVI withholding further disbursements*

18. Other conditions: N/A

Signed by,



On behalf of the GAVI Alliance

Hind Khatib-Othman

Managing Director, Country Programmes

21 October 2013

RWANDA – ROTAVIRUS VACCINE SUPPORT
This Decision Letter sets out the Programme Terms of a Programme

1. Country: Rwanda										
2. Grant Number: 1215-RWA-13a-X										
3. Date of Decision Letter : 21 October 2013										
4. Date of the Partnership Framework Agreement: 07 June 2013										
5. Programme Title: New Vaccine Support										
6. Vaccine type: Rotavirus										
7. Requested product presentation and formulation of vaccine: Rota, 3 dose(s)										
8. Programme Duration¹¹: 2012-2015										
9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement): <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 10px;"> <tr> <th style="width: 25%;"></th> <th style="width: 20%;">2012-2013</th> <th style="width: 20%;">2014</th> <th style="width: 20%;">2015</th> <th style="width: 15%;">Total¹²</th> </tr> <tr> <td>Programme Budget (US\$)</td> <td>US\$13,346,000¹³</td> <td>US\$5,055,500</td> <td>US\$5,540,500</td> <td>US\$23,942,000</td> </tr> </table>		2012-2013	2014	2015	Total ¹²	Programme Budget (US\$)	US\$13,346,000 ¹³	US\$5,055,500	US\$5,540,500	US\$23,942,000
	2012-2013	2014	2015	Total ¹²						
Programme Budget (US\$)	US\$13,346,000 ¹³	US\$5,055,500	US\$5,540,500	US\$23,942,000						
10. Vaccine Introduction Grant: N/A										
11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement)¹⁴ : <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 10px;"> <tr> <th style="width: 50%;">Type of supplies to be purchased with GAVI funds in each year</th> <th style="width: 25%;">2012-2013</th> <th style="width: 25%;">2014</th> </tr> <tr> <td>Number of Rotavirus vaccines doses</td> <td></td> <td>963,000</td> </tr> <tr> <td>Annual Amounts (US\$)</td> <td>US\$13,346,000¹⁵</td> <td>US\$5,055,500</td> </tr> </table>	Type of supplies to be purchased with GAVI funds in each year	2012-2013	2014	Number of Rotavirus vaccines doses		963,000	Annual Amounts (US\$)	US\$13,346,000 ¹⁵	US\$5,055,500	
Type of supplies to be purchased with GAVI funds in each year	2012-2013	2014								
Number of Rotavirus vaccines doses		963,000								
Annual Amounts (US\$)	US\$13,346,000 ¹⁵	US\$5,055,500								
12. Procurement agency: UNICEF. The Country shall release its Co-Financing Payments each year to UNICEF.										
13. Self-procurement: N/A										

¹¹ This is the entire duration of the programme.

¹² This is the total amount endorsed by GAVI for the entire duration of the programme. This should be equal to the total of all sums in the table.

¹³ This is the consolidated amount for all previous years.

¹⁴ This is the amount that GAVI has approved. Please amend the indicative Annual Amounts from previous years if that changes subsequently.

¹⁵ This is the consolidated amount for all previously approved years.

- 14. Co-financing obligations: Reference code:** 1215-RWA-13a-X-C - According to the Co-Financing Policy, the Country falls within the group Low Income. The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2014	2015
Number of vaccine doses	24,900	28,100
Value of vaccine doses (US\$)	US\$124,176	
Total Co-Financing Payments (US\$) (including freight)	US\$130,500	US\$145,500

- 15. Operational support for campaigns:** N/A

	2014	2015
Grant amount (US\$)		

- 16. Additional documents to be delivered for future disbursements:**


Reports, documents and other deliverables	Due dates
Annual Progress Report	15 May 2014

- 17. Financial Clarifications:** The Country shall provide the clarifications stated in the IRC report attached as appendix C to GAVI*.

**Failure to provide the financial clarifications requested may result in GAVI withholding further disbursements*

- 18. Other conditions:** N/A

Signed by,



On behalf of the GAVI Alliance

Hind Khatib-Othman

Managing Director, Country Programmes

21 October 2013